Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report for
2013, themed "Pioneer in Rare Diseases", on the company's website,
www.sobi.com.
The Annual Report summarises 2013, which was an eventful year for Sobi with
several key milestones, and encompasses the company's approach to keeping the
patient journey - from diagnosis and treatment, to on-going disease management
and long-term outcomes - at the centre of how it prioritises its capabilities
and investments. By creating and maintaining a dialogue with key stakeholders
(patients organisations, physicians, governments and payers), Sobi seeks to
ensure that treatments are delivered in a sustainable way. Sobi refers to this
approach as Patient and Customer Centric Commercialisation.
Sobi's Annual Report also includes interviews with key industry stakeholders as
well as patients, giving their perspective on the development of the
pharmaceutical industry and how it is to live with a rare disease, respectively.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with three late stage biological
development projects within Haemophilia and Neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
(€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations Investor relations
Oskar Bosson Jörgen Winroth
Head of Communications Vice President, Head of Investor
Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +46 8 697 2135
oskar.bosson@sobi.com jorgen.winroth@sobi.com
[HUG#1777618]
